Sernova Biotherapeutics (FRA:PSH0) Total Current Assets : €1.39 Mil (As of Jan. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Sernova Biotherapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Sernova Biotherapeutics's total current assets for the quarter that ended in Jan. 2025 was €1.39 Mil.

Sernova Biotherapeutics Total Current Assets Historical Data

The historical data trend for Sernova Biotherapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Total Current Assets Chart

Sernova Biotherapeutics Annual Data

Trend

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Total Current Assets

Get a 7-Day Free Trial

2.96

19.64

37.88

14.52

4.32

Sernova Biotherapeutics Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Total Current Assets	Get a 7-Day Free Trial															11.68	7.07	4.19	4.32	1.39

Sernova Biotherapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Sernova Biotherapeutics's Total Current Assets for the fiscal year that ended in Oct. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	4.012	+	0.199	+	0	+	0.106
	=	4.32

Sernova Biotherapeutics's Total Current Assets for the quarter that ended in Jan. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.811	+	0.25	+	0	+	0.327
	=	1.39

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Sernova Biotherapeutics (FRA:PSH0) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Sernova Biotherapeutics's Liquidation Value for the quarter that ended in Jan. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.811	-	14.103	+	0.75 * 0.25	+	0.5 * 0
=	-13.10

Sernova Biotherapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (FRA:PSH0) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

SEOVF:USA PSH0:Germany PSH0:Germany SVA:Canada

Address

700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.

Sernova Biotherapeutics Headlines

No Headlines